Current Therapies and Technological Advances in Aqueous Aerosol Drug Delivery

REFERENCES

• P. J. Anderson. (2001). Delivery options and devices for aerosolized therapeutics. Chest 120 (S3):89S–93S.
   PubMedGoogle Scholar
• P. Bartram. (2005). Use of a micropump nebulizer for aerosolized medication delivery in a ventilated infant. Neonatal Intensive Care 18 (1):14.
   Google Scholar
• P. K. P. Burnell, L. Asking, L. Borgstrom, S. C. Nichols, B. Olsson, D. Prime, and et al. (2007). Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV – the oropharyngeal retention effect for four inhalation delivery systems. J. Aerosol. Med. 20 (3):269–281.
   PubMedGoogle Scholar
• D. Cipolla, B. Boyd, R. Evans, S. Warren, G. Taylor, and S. Farr. (2000). Bolus administration of INS365: Studying the feasibility of delivering high dose drugs using the AERX pulmonary delivery system. Respir. Drug Deliv. 7:231–239.
   PubMedGoogle Scholar
• M. Cloupeau, and B. Prunet-Foch. (1989). Electrostatic spraying of liquids in cone-jet mode. J. Electron. 22:135–159.
   Web of Science ®Google Scholar
• T. E. Corcoran, J. H. Dauber, N. Chigier, and A. T. Iacono. (2002). Improving drug delivery from medical nebulizers: The effects of increased nebulizer flow rates and reservoirs. J. Aerosol Med. 15 (3):271–282.
   PubMedGoogle Scholar
• R. N. Dalby, M. Spallek, and T. Voshaar. (2004). A review of the development of respimat soft mist inhaler. Int. J. Pharm. 283:1–9.
   PubMed Web of Science ®Google Scholar
• W. H. DeHaan, and W. H. Finlay. (2001). In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices. J. Aerosol Med. 14 (3):361–367.
   PubMedGoogle Scholar
• J. Denyer, K. Nikander, and N. J. Smith. (2004). Adaptive aerosol delviery (AAD) technology. Expert Opinion Drug Deliv. 1 (1):165–176.
   PubMedGoogle Scholar
• D. S. Deshpande, J. D. Blanchard, J. Schuster, D. Fairbanks, C. Hobbs, R. Beihn, and et al. (2005). Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system. J. Aerosol Med. 18 (1):34–44.
   PubMedGoogle Scholar
• D. Deshpande, J. Blanchard, S. Srinivasan, D. Fairbanks, J. Fujimoto, T. Sawa, and et al. (2002). Aerosolization of lipoplexes using AERx pulmonary delivery system. AAPS PharmSci 4 (3):1–10.
   Google Scholar
• J. F. Dessanges. (2001). A history of nebulization. J. Aerosol Med. 14:65–71.
   PubMedGoogle Scholar
• R. Dhand. (2005). Aerosol plumes: Slow and steady wins the race. J. Aerosol Med. 18 (3):261–263.
   PubMedGoogle Scholar
• A. M. A. Elhissi, M. Faizi, W. F. Naji, H. S. Gill, and K. M. G. Taylor. (2007). Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int. J. Pharm. 334:62–70.
   PubMed Web of Science ®Google Scholar
• A. M. A. Elhissi, and K. M. G. Taylor. (2005). Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers. J. Drug Deliv. Sci. Technol. 15 (4):261–265.
   Web of Science ®Google Scholar
• S. Farr, S. Warren, P. Lloyd, J. Okikawa, J. Schuster, A. Rowe, and et al. (2000). Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. Int. J. Pharm. 198:63–70.
   PubMed Web of Science ®Google Scholar
• S. J. Farr, A. McElduff, L. E. Mather, J. Okikawa, M. E. Ward, I. Gonda, and et al. (2000). Pulmonary insulin administration using the AERx® system: Physicological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol. Ther. 2:185–197.
   PubMedGoogle Scholar
• W. H. Finlay, C. F. Lange, M. King, and D. P. Speert. (2000). Lung delivery of aerosolized dextran. Am. J. Respir. Crit. Care Med 161:91–97.
   PubMed Web of Science ®Google Scholar
• W. H. Finlay, and A. R. Martin. (2007). Modeling of aerosol deposition with interface devices. J. Aerosol Med. 20 (S1):S19–S28.
   PubMedGoogle Scholar
• D. Geller, J. Thipphawong, B. Otulana, D. Caplan, D. Ericson, L. Milgram, and et al. (2003). Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis. J. Aerosol Med. 16 (2):175–182.
   PubMedGoogle Scholar
• T. Ghazanfari, A. M. A. Elhissi, Z. Ding, and K. M. G. Taylor. (2007). The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int. J. Pharm. 339:103–111.
   PubMed Web of Science ®Google Scholar
• B. K. Gurses, and G. C. Smaldone. (2003). Effect of tubing depostion, breathing pattern, and temperature on aerosol mass distribution measured by cascade impactor. J. Aerosol Med. 16 (4):387–394.
   PubMedGoogle Scholar
• R. R. Henry, S. R. D. Mudaliar, W. C. Howland, N. Chu, D. Kim, B. An, and et al. (2003). Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care 26:764–769.
   PubMed Web of Science ®Google Scholar
• K. Hermansen, T. Ronnemaa, A. H. Petersen, S. Bellaire, and U. Adamson. (2004). Intensive therapy with inhaled insulin via the AERx insulin diabetes management system. Diabetes Care 27 (1):162–167.
   PubMed Web of Science ®Google Scholar
• D. R. Hess, D. Fisher, P. Williams, S. Pooler, and R. M. Kacmarek. (1996). Medication nebulizer performance. Effects of diluant volume. Chest 110 (2):498–505.
   PubMed Web of Science ®Google Scholar
• M. Hindle. Soft mist inhalers: A review of current technology The Drug Delivery Companies Report(Autumn/Winter). (2004), 31–34.
   Google Scholar
• S. L. Ho, W. T. J. Kwong, L. O'Drowsky, and A. L. Coates. (2001). Evaluation of four breath-enhanced nebulizers for home use. J. Aerosol Med. 14 (4):467–475.
   PubMedGoogle Scholar
• D. Hochrainer, H. Holz, C. Kreher, L. Scaffidi, M. Spallek, and H. Wachtel. (2005). Comparison of the aerosol velocity and spray duration of Respimat Soft Mist Inhaler and pressurized metered dose inhalers. J. Aerosol Med. 18 (3):273–282.
   PubMedGoogle Scholar
• C. Kapitza, M. Hompesch, B. Scharling, and T. Heise. (2004). Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol. Ther. 6 (4):466–472.
   PubMedGoogle Scholar
• F. Kassner, R. Hodder, and E. D. Bateman. (2004). A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered Via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease. Drugs 64 (15):1671–1682.
   PubMed Web of Science ®Google Scholar
• S. A. Kilfeather, H. H. Pointz, E. Beck, P. Schmidt, A. Lee, I. Bowen, and et al. (2004). Improved delivery of ipratropium bromide/fenoterol from respimat soft mist inhaler in patients with COPD. Respir. Med. 98 (5):387–397.
   PubMed Web of Science ®Google Scholar
• E. Kohler, V. Sollich, R. Schuster-Wonka, and J. Huhnerbein. (2003). Lung deposition in cystic fibrosis patients using an ultrasonic or a jet nebulizer. J. Aerosol Med. 16 (1):37–46.
   PubMedGoogle Scholar
• N. V. Koshkina, E. Golunski, L. E. Roberts, B. E. Gilbert, and V. Knight. (2004). Cyclosporin a aerosol improves the anticancer effect of paclitaxel aerosol in mice. J. Aerosol Med. 17 (1):7–14.
   PubMedGoogle Scholar
• C. F. Lange, and W. H. Finlay. (2006). Liquid atomizing: Nebulizing and other methods of producing aerosols. J. Aerosol Med. 19 (1):28–35.
   PubMedGoogle Scholar
• B. L. Laube. (2001). Treating diabetes with aerosolized insulin. Chest 120 (3):S99–S106.
   PubMed Web of Science ®Google Scholar
• Y. K. Lentz, T. J. Anchordoquy, and C. S. Lengsfeld. (2006). Rationale for the selection of an aerosol delivery system for gene delivery. J. Aerosol Med. 19 (3):372–384.
   PubMedGoogle Scholar
• Y. K. Lentz, L. R. Worden, T. J. Anchordoquy, and C. S. Lengsfeld. (2005). Effect of jet nebulization on DNA: Identifying the dominant degradation mechanism and mitigation methods. Aerosol Sci. 36:973–990.
   Web of Science ®Google Scholar
• K. Leung, E. Louca, and A. L. Coates. (2004). Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest 126 (5):1619–1627.
   PubMed Web of Science ®Google Scholar
• J. Lynch, N. Behan, and C. Birkinshaw. (2007). Factors controlling particle size during nebulization of DNA-polycation complexes. J. Aerosol Med. 20 (3):257–268.
   PubMedGoogle Scholar
• L. E. Mather, A. Woodhouse, M. E. Ward, S. J. Farr, R. Rubsamen, and L. G. Eltherington. (1998). Pulmonary administration of aerosolised fentanyl: Pharmacokinetic analysis of systemic delivery. Br. J. Clin. Pharmacol. 46:37–43.
   PubMed Web of Science ®Google Scholar
• O. N. M. McCallion, K. M. G. Taylor, P. A. Bridges, M. Thomas, and A. J. Taylor. (1996). Jet nebulisers for pulmonary drug delivery. Int. J. Pharm. 130:1–11.
   Web of Science ®Google Scholar
• S. McGuire. (2006). The I-neb adaptive aerosol delivery (AAD) system – a holistic approach to inhaled drug delivery including regulatory approval. Drug Deliv. Rep., (Spring/Summer) 6:8–71.
   Google Scholar
• T. T. Mercer. (1981). Production of therapeutic aerosols: Principles and techniques. Chest 80 (6 suppl):813–818.
   PubMed Web of Science ®Google Scholar
• C. Mitsakou, C. Helmis, and C. Housiadas. (2005). Eulerian modeling of lung deposition with sectional representation of aerosol dynamics. Aerosol Sci. 36:75–94.
   Web of Science ®Google Scholar
• S. P. Newman, J. Brown, K. P. Steed, S. J. Reader, and H. Kladders. (1998). Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: Comparison of Respimat with conventional metered-dose inhalers with and without spacer devices. Chest 113:957–963.
   PubMed Web of Science ®Google Scholar
• S. Newman, and A. Gee-Turner. (2005). The omron MicroAir vibrating mesh technology nebulizer, a 21st century approach to inhalation therapy. J. Appl. Ther. Res 5 (4):29–33.
   Google Scholar
• S. P. Newman, D. Pavia, F. Moren, N. F. Sheahan, and S. W. Clarke. (1981). Deposition of pressurised aerosols in the human respiratory tract. Thorax 36:52–55.
   PubMed Web of Science ®Google Scholar
• S. P. Newman, K. P. Steed, M. Phil, S. J. Reader, D. Pavia, and A. K. Sohal. (2007). An in vitro study to assess facial and ocular deposition from Respimat Soft Mist Inhaler. J. Aerosol Med. 20 (1):7–12.
   PubMedGoogle Scholar
• K. Nikander, L. Arheden, J. Denyer, and N. Cobos. (2003). Parents’ adherence with nebulizer treatment of their children when using an adaptive aerosol delivery (AAD) system. J. Aerosol Med. 16 (3):2003.
   Google Scholar
• K. Nikander, J. Denyer, M. Everard, and G. C. Smaldone. (2000). Validation of a new breathing simulator generating and measuring inhaled aerosol with adult breathing patterns. J. Aerosol Med. 13 (2):139–146.
   PubMedGoogle Scholar
• K. Nikander, J. Denyer, N. Smith, and P. Wollmer. (2001). Breathing patterns and aerosol delivery: Impact of regular human patterns, and sine and square waveforms on rate of delivery. J. Aerosol Med. 14 (3):327–333.
   PubMedGoogle Scholar
• L. V. None, D. Grimbert, J. Bordenave, G. Benoit, Y. Furet, B. Fauroux, and et al. (2004). Residual gravimetric method to measure nebulizer output. J. Aerosol Med. 17 (1):63–71.
   PubMedGoogle Scholar
• F. W. Okumu, R. Y. Lee, J. D. Blanchard, A. Queirolo, C. M. Woods, P. M. Lloyd, and et al. (2002). Evaluation of the AERx pulmonary delivery system for the systemic delivery of a poorly soluble selective D-1 agonist ABT-431. Pharm. Res. 19 (7):1009–1012.
   PubMed Web of Science ®Google Scholar
• C. O'Callaghan, and P. W. Barry. (1997). The science of nebulised drug delivery. Thorax 52:31–44.
   PubMed Web of Science ®Google Scholar
• C. O'Callaghan, and P. Wright. The metered dose inhaler. Drug delivery to the lungC. Bisgaard, C. O'Callaghan, and G. C. Smaldone. Marcel Dekker, New York, (2002), 337–370.
   Google Scholar
• K. M. Pedersen, V. N. Handlos, L. Heslet, and G. Kristensen. (2006). Factors influencing the in vitro deposition of tobramycin aerosol: A comparison of an ultrasonic nebulizer and a high-frequency vibrating mesh nebulizer. J. Aerosol Med. 19 (2):175–183.
   PubMedGoogle Scholar
• G. R. Pitcairn, S. J. Reader, D. Pavia, and S. P. Newman. (2005). Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist Inhaler compared to deposition by metered dose inhaler or Turbuhaler Dry Powder Inhaler. J. Aerosol Med. 18 (3):264–272.
   PubMedGoogle Scholar
• R. Potter, I. Prince, T. Dyche, R. H. M. Hatley, and N. J. Smith. (2005). Abstracts from the international society for aerosols in medicine. J. Aerosol Med. 18 (1):112–113.
   Google Scholar
• A. P. Roth, C. F. Lange, and W. H. Finlay. (2003). The effect of breathing pattern on nebulizer drug delivery. J. Aerosol Med. 16 (3):325–329.
   PubMedGoogle Scholar
• S. Sanjar, and J. Matthews. (2001). Treating systemic diseases via the lung. J. Aerosol Med. 14 (S1):S51–S58.
   PubMedGoogle Scholar
• K. G. Schuepp, J. Jauernig, H. M. Janssens, H. A. W. M. Tiddens, D. A. Straub, R. Stangl, and et al. (2005). In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J. Aerosol Med. 18 (2):225–235.
   PubMedGoogle Scholar
• J. Schuster, S. Farr, D. Cipolla, T. Wilbanks, J. Rosell, P. Lloyd, and et al. (1998). Design performance validation of a highly efficient and reproducible compact aerosol delivery system: AERx®. Respir.Drug Deliv. 6:83–90.
   Google Scholar
• J. Schuster, R. Rubsamen, P. Lloyd, and J. Lloyd. (1997). The AERx® aerosol delivery system. Pharm. Res. 14 (3):354–357.
   PubMed Web of Science ®Google Scholar
• J. Shaw. (2004). Aerogen impacts pulmonary drug delivery in the acute care setting. Drug Deliv. Technol. 4 (6):1–3.
   Google Scholar
• V. L. Silkstone, J. H. Dennis, C. A. Pieron, and H. Chrystyn. (2002). An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems. J. Aerosol Med. 15 (3):251–259.
   PubMedGoogle Scholar
• G. C. Smaldone. (2006). Advances in aerosols: Adult respiratory disease. J. Aerosol Med. 19 (1):36–46.
   PubMedGoogle Scholar
• K. Smith. (2004). The advantages of nebulization in the treatment of mechanically ventilated neonates. Neonatal Intensive Care 17 (3):12–16.
   Google Scholar
• E. C. Smith, J. Denyer, and A. H. Kendrick. (1995). Comparison of twenty-three nebulizer/compressor combinations in domiciliary use. Eur. Respir. J. 8:1214–1221.
   PubMed Web of Science ®Google Scholar
• M. Spallek, D. Hochrainer, and H. Wachtel. (2002). Optimizing nozzles for soft mist inhalers. Respir. Drug Deliv. 8 (2):375–378.
   Google Scholar
• K. M. G. Taylor, and O. N. M. McCallion. (1997). Ultrasonic nebulisers for pulmonary drug delivery. Int. J. Pharm. 153:93–104.
   Web of Science ®Google Scholar
• J. B. Thipphawong, N. Babul, R. J. Morishige, H. K. Findlay, K. R. Reber, G. J. Millward, and et al. (2003). Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology 99 (3):693–700.
   PubMed Web of Science ®Google Scholar
• R. E. Van Dyke, and K. Nikander. (2007). Delivery of Iloprost inhalation solution with the HaloLite, Prodose, and I-neb adaptive aerosol delivery systems: An in vitro study. Respir. Care 52 (2):184–190.
   PubMed Web of Science ®Google Scholar
• T. Voshaar, R. Lapidus, R. Maleki-Yazdi, W. Timmer, E. Rubin, L. Lowe, and et al. (2006). A randomised study of tiotropium Respimat Soft Mist Inhaler versus ipratropium pMDI in chronic obstructive pulmonary disease. Thorax 61 (S2):ii40.
   Google Scholar
• A. Wagner, K. Vorauer-Uhl, and H. Katinger. (2006). Nebulization of liposomal rh-cu/zn-SOD with a novel vibrating membrane nebulizer. J. Liposome Res. 16:113–125.
   PubMed Web of Science ®Google Scholar
• J. C. Waldrep. (1998). New aerosol drug delivery systems for the treatment of immune-mediated pulmonary diseases. Drugs Today 34 (6):549–561.
   PubMed Web of Science ®Google Scholar
• J. C. Waldrep, A. Berlinski, and R. Dhand. (2007). Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. J. Aerosol Med. 20 (3):310–319.
   PubMedGoogle Scholar
• M. E. Ward, A. Woodhouse, L. E. Mather, S. J. Farr, J. Okikawa, P. Lloyd, and et al. (1997). Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clinical Pharmacol. Ther. 62 (6):596–609.
   PubMed Web of Science ®Google Scholar
• L. Williams. Novel pulmonary delivery technology [electronic version]. Pharma-Mag.. (2007), 4–5.
   Google Scholar
• L. Wilson, R. Simmons, and P. S. Uster. Aerosol characteristics of adeno-associated viral vectors produced by an electronic micropump inhaler, Poster presented at the Cystic Fibrosis Foundation Meeting, (2003)
   Google Scholar
• Pieber Wollmer, T. R. M. Gall, and S. Brunton. (2007). Delivering needle-free insulin using AERx iDMS technology. Diabetes Technol. Ther. 9 (Suppl 1):S57–S63.
   PubMedGoogle Scholar
• B. M. Z. Zainudin, M. Biddiscombe, S. E. J. Tolfree, M. Short, and S. G. Spiro. (1990). Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 45:469–473.
   PubMed Web of Science ®Google Scholar
• W. C. Zimlich, J. Y. Ding, D. R. Busick, R. R. Moutvic, M. E. Placke, P. H. Hirst, and et al. (2000). The development of a novel electrohydrodynamic pulmonary drug delivery device. Respir. Drug Deliv. 7:241–246.
   Google Scholar